A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle.
Analogs or derivatives of prostaglandins F that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal PGF.
Compounds obtained by chemical synthesis that are analogs or derivatives of naturally occurring prostaglandins and that have similar activity.
Degradation of CORPUS LUTEUM. In the absence of pregnancy and diminishing trophic hormones, the corpus luteum undergoes luteolysis which is characterized by the involution and cessation of its endocrine function.
The yellow body derived from the ruptured OVARIAN FOLLICLE after OVULATION. The process of corpus luteum formation, LUTEINIZATION, is regulated by LUTEINIZING HORMONE.
Chemical compounds causing LUTEOLYSIS or degeneration.
Occurrence or induction of ESTRUS in all of the females in a group at the same time, applies only to non-primate mammals with ESTROUS CYCLE.
The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.
A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.
The period in the ESTROUS CYCLE associated with maximum sexual receptivity and fertility in non-primate female mammals.
The final period of OBSTETRIC LABOR that is from the expulsion of the FETUS to the expulsion of the PLACENTA.
A genus of the subfamily CALLITRICHINAE occurring in forests of Brazil and Bolivia and containing seventeen species.
The discharge of an OVUM from a rupturing follicle in the OVARY.
Gonadotropins secreted by the pituitary or the placenta in horses. This term generally refers to the gonadotropins found in the pregnant mare serum, a rich source of equine CHORIONIC GONADOTROPIN; LUTEINIZING HORMONE; and FOLLICLE STIMULATING HORMONE. Unlike that in humans, the equine LUTEINIZING HORMONE, BETA SUBUNIT is identical to the equine choronic gonadotropin, beta. Equine gonadotropins prepared from pregnant mare serum are used in reproductive studies.
A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.
Premature expulsion of the FETUS in animals.
Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157)
The period in the MENSTRUAL CYCLE that follows OVULATION, characterized by the development of CORPUS LUTEUM, increase in PROGESTERONE production by the OVARY and secretion by the glandular epithelium of the ENDOMETRIUM. The luteal phase begins with ovulation and ends with the onset of MENSTRUATION.
Any of the ruminant mammals with curved horns in the genus Ovis, family Bovidae. They possess lachrymal grooves and interdigital glands, which are absent in GOATS.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
(9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics.
Intentional removal of a fetus from the uterus by any of a number of techniques. (POPLINE, 1978)
A water-soluble polypeptide (molecular weight approximately 8,000) extractable from the corpus luteum of pregnancy. It produces relaxation of the pubic symphysis and dilation of the uterine cervix in certain animal species. Its role in the human pregnant female is uncertain. (Dorland, 28th ed)
A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.
Artificial introduction of SEMEN or SPERMATOZOA into the VAGINA to facilitate FERTILIZATION.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.
An OOCYTE-containing structure in the cortex of the OVARY. The oocyte is enclosed by a layer of GRANULOSA CELLS providing a nourishing microenvironment (FOLLICULAR FLUID). The number and size of follicles vary depending on the age and reproductive state of the female. The growing follicles are divided into five stages: primary, secondary, tertiary, Graafian, and atretic. Follicular growth and steroidogenesis depend on the presence of GONADOTROPINS.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Ovarian follicular responses in dairy cows treated with GnRH and cloprostenol. (1/180)

Lactating, nonpregnant (with a corpus luteum) Holsteins were given 100 ug GnRH (n = 12) or saline (n = 12) and 500 ug cloprostenol 6 d later. Following luteolysis, ovulation occurred 10.1 +/- 0.2 d (range, 9-12 d) after GnRH and 8.6 +/- 1.0 d (range, 3-12 d) after saline (differences between groups: means, P > 0.05; variability, P < 0.001). Treatment with GnRH and cloprostenol resulted in a relatively synchronous ovulation.  (+info)

Synchronization of estrus in beef cattle with norgestomet and estradiol valerate. (2/180)

Fifty-six cows received a norgestomet implant and an injection of norgestomet and estradiol valerate; half (n = 28) received 500 IU equine chorionic gonadotrophin (eCG) at implant removal, 9 d later. A third group (n = 25) received 2 doses of cloprostenol (500 micrograms) 11 d apart. Estrous rate was higher (P < 0.05) for cows given norgestomet and estradiol plus 500 IU eCG (75.0%) than for those receiving cloprostenol (44.0%); for those receiving norgestomet and estradiol alone, it was intermediate (67.8%). Pregnancy rates to artificial insemination (after estrus or timed) were higher (P < 0.05) for cows given norgestomet and estradiol than for those given cloprostenol (23 of 28, 82.1% vs 13 of 25, 52.0%), and intermediate (67.8%) for those given norgestomet and estradiol plus eCG. In a second experiment, for heifers treated with norgestomet and estradiol plus eCG (n = 15) or with 2 doses of cloprostenol (n = 16), estrous rates were 66.7% vs 56.2% (P > 0.5), ovulation rates were 100.0% vs 81.2% (P = 0.08), intervals from implant removal or cloprostenol treatment to estrus were 48.0 +/- 4.4 hours vs 61.3 +/- 7.0 hours (P = 0.12) and to ovulation were 70.4 +/- 4.4 hours vs 93.2 +/- 7.5 hours (P < 0.01), respectively; pregnancy rates were 41.7 and 35.7%, respectively (P > 0.5). Norgestomet and estradiol were as good as (heifers) or superior to (cows) a 2-dose cloprostenol regimen. In cows given norgestomet and estradiol, injecting eCG at implant removal did not significantly improve estrous or pregnancy rates.  (+info)

Functional evidence for divergent receptor activation mechanisms of luteotrophic and luteolytic events in the human corpus luteum. (3/180)

Using a dispersed human luteal cell culture model, progesterone synthesis following treatment by incremental doses of human chorionic gonadotrophin (HCG) and the stable prostaglandin F2alpha (PGF2alpha) analogue cloprostenol, alone or in combination, was related to corpora lutea (CL) mRNA transcript abundance coding for the luteinizing hormone (LH)/HCG receptor (LH-R) and PGF2alpha-receptor (FP) by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) in 33 otherwise healthy women, scheduled for surgery due to benign conditions. CL were grouped according to age, based on the occurrence of a preovulatory LH surge where post-LH days 2-5 were designated as early luteal phase, days 6-10 as mid-luteal phase and days 11-14 as late luteal phase. When exposed to HCG, maximal progesterone output was raised 2.2-fold (P = 0.08, n = 5) compared with untreated controls in the early CL, while it increased 5.7- and 4.6-fold in the mid- and late groups respectively (P<0.05, n = 4 mid-luteal phase, n = 3 late luteal phase). This stimulation pattern was found to be concordant with the value of mRNA coding for LH-R in all groups (n = 6 early luteal phase, n = 5 mid-luteal phase, n = 6 late luteal phase). The integrated response to HCG and cloprostenol showed a dose-dependent 60% inhibition of progesterone production; but only in late luteal phase luteal cells (P<0.01, n = 3). FP mRNA values were lowest in early luteal phase, and increased with the age of the CL. Interestingly, lowest CL tissue concentrations of the natural FP agonist PGF2alpha were found during mid-luteal phase while it increased again 1.6-fold during late luteal phase (P<0.05, n = 8 versus mid-luteal phase, n = 6). Collectively, these data demonstrate that (i) the extrinsic functional control (or rescue of CL in the event of pregnancy) occurs when the sensitivity towards LH/HCG is maximal; and (ii) the demise of CL function is mediated via an acquisition of sensitivity towards the intrinsic luteolytic signal, PGF2alpha in the ageing CL.  (+info)

Effect of sodium cloprostenol and flunixin meglumine on luteolysis and the timing of birth in bitches. (4/180)

At birth, the physiological role of prostaglandins in bitches is unclear. Bitches were treated before parturition with either saline, the prostaglandin analogue, sodium cloprostenol, or the prostaglandin synthetase inhibitor, flunixin meglumine. The animals were examined regularly to determine the onset of parturition and a series of blood samples were taken to define the hormonal profiles before, during and after birth. Animals treated with cloprostenol whelped earlier than did controls. In addition, the prostaglandin F2 alpha metabolite surge and decrease in plasma progesterone concentration and rectal temperature were earlier than in controls. Flunixin meglumine disrupted the normal 13,14-dihydro-15-keto prostaglandin F2 alpha profile but did not abolish prostaglandin synthesis completely or delay the onset of labour in treated animals. This study confirms that prostaglandins induce luteolysis and the onset of labour in the bitch. However, the partial inhibition of prostaglandin synthesis does not prevent parturition.  (+info)

Source and site of action of anti-luteolytic interferon in red deer (Cervus elaphus): possible involvement of extra-ovarian oxytocin secretion in maternal recognition of pregnancy. (5/180)

Six conceptuses were collected from red deer hinds on day 22 after synchronization of oestrus with intravaginal progesterone-releasing devices (removal of device = day 0). Within 24 h of culture in vitro, the supernatant from five of six conceptuses showed detectable antiviral activity. Interferon alpha (IFN-alpha) receptors were identified by immunohistochemistry on the luminal surface of the endometrium, in the neurohypophysis and paraventricular hypothalamus, but not in the ovaries of the hinds from which the conceptuses were collected. Another 16 intact hinds were synchronized as above. Injection of 4 mg IFN i.m. twice a day on days 13-15 had no effect on cloprostenol-induced oxytocin secretion on day 15 and did not prevent cloprostenol-induced luteal regression. Sixteen ovariectomized hinds received a protocol of steroid treatment to mimic ovarian hormone secretion during the normal oestrous cycle. On day 16, hinds showed undulant oxytocin secretion that showed a degree of temporal association with uterine PGF2 alpha release. Treatment with 4 mg IFN-alpha I 1 twice a day on days 13-16 had no effect on this spontaneous oxytocin secretion, but reduced the magnitude of cloprostenol-induced oxytocin secretion on day 17 (P < 0.05). These results indicate that red deer conceptuses secrete an anti-luteolytic IFN to which the endometrium expresses a receptor during early pregnancy. The presence of IFN receptors in the hypothalamus and posterior pituitary and the IFN-induced suppression of extra-ovarian oxytocin secretion provides tentative evidence of an involvement of the central nervous system in maternal recognition of pregnancy in deer.  (+info)

Direct effects of ovine follicular fluid on ovarian steroid secretion and expression of markers of cellular differentiation in sheep. (6/180)

The objective of this study was to assess the effect of ovine follicular fluid (FF) treatment (with or without FSH replacement) during the late follicular phase on plasma concentrations of gonadotrophins and the development of the ovulatory follicle. Ovarian steroid secretion and expression of mRNA encoding inhibin alpha and beta A, beta B subunits, P450 aromatase and P450 17 alpha-hydroxylase were used as endpoints. After induction of luteolysis by injection of 100 micrograms cloprostenol on days 10-12, Scottish Blackface ewes were allocated to one of three groups: (1) control (n = 7): no further treatment; (2) FF (n = 9): subcutaneous injections of 3 ml steroid-free ovine follicular fluid at 9 h intervals, 18 and 27 h after cloprostenol injection; (3) FF + FSH (n = 8): injections of follicular fluid as above plus subcutaneous injections of 0.36 iu ovine FSH at 6 h intervals, 18, 24, and 30 h after cloprostenol injection. Jugular venous blood samples were obtained via indwelling cannulae at 6 h intervals from 0 to 36 h after cloprostenol injection, and at 10 min intervals from 12 to 18 h (control phase) and from 30 to 36 h after cloprostenol injection (treatment phase). At laparotomy, 36 h after cloprostenol injection, ovarian venous blood was collected and ovaries were removed and processed for in situ hybridization. Plasma concentrations of FSH, luteinizing hormone (LH) and oestradiol were determined by radioimmunoassay. Follicular fluid treatment resulted in a decrease (P < 0.001) in FSH concentrations associated with an acute decrease in ovarian steroid secretion (P < 0.01) and a specific depression in P450 aromatase, (P < 0.001), inhibin-activin beta B subunit (P < 0.05) and thecal LH receptor (P < 0.001) expression. Follicular fluid treatment had no effect on inhibin-activin alpha and beta A, subunit or P450 17 alpha-hydroxylase expression. FSH co-treatment with follicular fluid restored circulating FSH concentrations to normal values and reversed some of the effects of follicular fluid (androstenedione, testosterone and progesterone secretion, and inhibin beta B and thecal LH receptor expression) but not oestradiol secretion or P450 aromatase expression. It was concluded that the actions of follicular fluid are mediated via both central effects on pituitary FSH secretion and by direct ovarian effects on granulosa cell aromatase activity. The results indicate that follicular fluid contains a factor that inhibits aromatase activity of granulosa cells directly and may play a role in the selection of the dominant follicle.  (+info)

Relationship between the responsiveness to multiple-ovulation treatment and the number of bovine oocytes collected by transvaginal follicle aspiration. (7/180)

To characterize factors affecting the number of bovine oocytes recovered transvaginally, a regression analysis was performed between the responsiveness to multiple-ovulation treatment and the number of oocytes recovered transvaginally. The number of embryos recovered following multiple-ovulation treatment and the number of oocytes recovered transvaginally increased when the number of follicles to be aspirated transvaginally increased (P<0.05. P<0.01). The number of cumulus-oocyte complexes recovered transvaginally also increased when the number of oocytes to be aspirated transvaginally increased (P<0.001). However, the number of viable embryos that recovered following multiple-ovulation treatment had no relation to the number of cumulus-oocyte complexes recovered transvaginally. These results suggested that more oocytes can be recovered from donors that have a high responsiveness to multiple-ovulation treatment.  (+info)

Prostaglandin f(2alpha) induces distinct physiological responses in porcine corpora lutea after acquisition of luteolytic capacity. (8/180)

This study examines differences in intracellular responses to cloprostenol, a prostaglandin (PG)F(2alpha) analog, in porcine corpora lutea (CL) before (Day 9 of estrous cycle) and after (Day 17 of pseudopregnancy) acquisition of luteolytic capacity. Pigs on Day 9 or Day 17 were treated with saline or 500 microgram cloprostenol, and CL were collected 10 h (experiment I) or 0.5 h (experiment III) after treatment. Some CL were cut into small pieces and cultured to measure progesterone and PGF(2alpha) secretion. In experiment I, progesterone remained high and PGF(2alpha) low in luteal incubations from either Day 9 or Day 17 saline-treated pigs. Cloprostenol increased PGF(2alpha) production 465% and decreased progesterone production 87% only from Day 17 luteal tissue. Cloprostenol induced prostaglandin G/H synthase (PGHS)-2 mRNA (0.5 h) and protein (10 h) in both groups. In cell culture, cloprostenol or phorbol 12, 13-didecanoate (PDD) (protein kinase C activator), induced PGHS-2 mRNA in luteal cells from both groups. However, acute cloprostenol treatment (10 min) decreased progesterone production and increased PGF(2alpha) production only from Day 17 luteal cells. Thus, PGF(2alpha) production is induced by cloprostenol in porcine CL with luteolytic capacity (Day 17) but not in CL without luteolytic capacity (Day 9). However, this change in PGF(2alpha) production is not explained by a difference in induction of PGHS-2 mRNA or protein.  (+info)


Veterinary abortion refers to the intentional termination of a pregnancy in an animal, typically a farm or domesticated animal such as a dog, cat, horse, cow, or pig. The procedure is performed by a veterinarian and is usually done for reasons such as unwanted breeding, disease or genetic disorders in the fetus, or to prevent overpopulation of certain species.

Types of Veterinary Abortion:

1. Spontaneous Abortion (Miscarriage): This occurs naturally when the pregnancy is terminated by natural causes such as infection or trauma.
2. Induced Abortion: This is performed by a veterinarian using various methods such as injection of drugs or surgical procedures to terminate the pregnancy.

Methods of Veterinary Abortion:

1. Drug-induced abortion: This method involves administering medication to the animal to cause uterine contractions and expulsion of the fetus.
2. Surgical abortion: This method involves surgical intervention to remove the fetus from the uterus, usually through a small incision in the abdomen.
3. Non-surgical abortion: This method uses a device to remove the fetus from the uterus without making an incision.

Complications and Risks of Veterinary Abortion:

1. Infection: As with any surgical procedure, there is a risk of infection.
2. Hemorrhage: Excessive bleeding can occur during or after the procedure.
3. Uterine rupture: In rare cases, the uterus may rupture during the procedure.
4. Incomplete abortion: In some cases, not all of the fetus may be removed, leading to complications later on.
5. Scarring: Scars may form in the uterus or abdomen after the procedure, which can lead to reproductive problems in the future.

Prevention of Unwanted Pregnancies in Animals:

1. Spaying/neutering: This is the most effective way to prevent unwanted pregnancies in animals.
2. Breeding management: Proper breeding management, including selecting healthy and fertile breeding animals, can help reduce the risk of unwanted pregnancies.
3. Use of contraceptives: Hormonal contraceptives, such as injection or implants, can be used in some species to prevent pregnancy.
4. Behavioral management: In some cases, behavioral management techniques, such as separation or rehoming of animals, may be necessary to prevent unwanted breeding.

Ethical Considerations of Veterinary Abortion:

1. Animal welfare: The procedure should only be performed when necessary and with the intention of improving the animal's welfare.
2. Owner consent: Owners must provide informed consent before the procedure can be performed.
3. Veterinarian expertise: The procedure should only be performed by a licensed veterinarian with experience in the procedure.
4. Alternative options: All alternative options, such as spaying/neutering or rehoming, should be considered before performing an abortion.


Veterinary abortion is a complex issue that requires careful consideration of ethical and practical factors. While it may be necessary in some cases to prevent the suffering of unwanted litters, it is important to approach the procedure with caution and respect for animal welfare. Owners must provide informed consent, and the procedure should only be performed by a licensed veterinarian with experience in the procedure. Alternative options, such as spaying/neutering or rehoming, should also be considered before performing an abortion. Ultimately, the decision to perform a veterinary abortion should be made with the intention of improving the animal's welfare and quality of life.

... is a synthetic analogue of prostaglandin F2α (PGF2α). It is a potent luteolytic agent; this means that, within ... Plumb DC (2015). "Cloprostenol Sodium". Plumb's Veterinary Drug Handbook (8th ed.). Wiley. ISBN 9781118911938. v t e (ECHA ...
Cloprostenol is another example of such an agent. "Luteolysis - Google Search". www.google.com. Retrieved 2020-12-18. McCracken ...
... cloprostenol MeSH D10.251.355.255.775 - thromboxanes MeSH D10.251.355.310 - fatty acids, essential MeSH D10.251.355.310.166 - ...
... cloprostenol, Δ9-tetrahydrocannabinol Delta (computer), a Russian ZX Spectrum clone Delta encoding or delta compression, a ...
... cloprostenol (INN) cloprothiazole (INN) cloquinate (INN) cloquinozine (INN) cloracetadol (INN) cloral betaine (INN) ...
G02AD02 Dinoprostone G02AD03 Gemeprost G02AD04 Carboprost G02AD05 Sulprostone G02AD06 Misoprostol QG02AD90 Cloprostenol ...
The synthetic analogs that like PGF2α act as selective receptor agonists of FP viz., cloprostenol, flupostenol, latanoprost, ...
... cloprostenol MeSH D23.767.193.184 - bilirubin MeSH D23.767.193.184.200 - biliverdine MeSH D23.767.193.727 - urobilin MeSH ...
A single intramuscular injection of 0.5 micrograms cloprostenol was not luteolytic on Day 6 or 7 of the ovarian cycle (N = 3), ... Cloprostenol-induced luteolysis in the marmoset monkey (Callithrix jacchus) P M Summers et al. J Reprod Fertil. 1985 Jan. ... Cloprostenol-induced luteolysis in the marmoset monkey (Callithrix jacchus) P M Summers, C J Wennink, J K Hodges ... The interval from cloprostenol injection to ovulation in animals treated between Days 8 and 17 was 10.7 +/- 0.3 days. A similar ...
Quality Cloprostenol - Veterinary Medicine - find quality Reproductive System, Veterinary Medicine & Reproductive System from ... INQUIRY ABOUT Cloprostenol - Veterinary MedicineVETERINARY MEDICINE IMPORT EXPORT JOINT STOCK COMPANY ...
Cloprostenol-induced luteolysis in the marmoset monkey (Callithrix jacchus). J Reprod Fertil. 1985;73(1):133-138. [PubMed: ... Of the available injections, one needs to be administered 3 weeks postpartum and then monthly (Cloprostenol) and another must ... Suppression with an LHRH antagonist and cloprostenol. J Endocrinol. 1991;128(3):465-473. [PubMed: 2013750] ...
3. Cloprostenol, a prostaglandin F(2alpha) analog, induces hypoxia in rat placenta: BOLD contrast MRI.. Girsh E; Plaks V; Gilad ... Luteolytic effects of cloprostenol sodium in lactating dairy cows treated with G6G/Ovsynch.. Martins JP; Policelli RK; Pursley ...
Cloprostenol Sodium Narrower Concept UI. M0351575. Registry Number. 886SAV9675. Terms. Cloprostenol Sodium Preferred Term Term ... Cloprostenol Monosodium Salt Cloprostenol Sodium Estrumate ICI-80,966 Oestrophan Pharm Action. Luteolytic Agents. Registry ... Cloprostenol Monosodium Salt Term UI T360764. Date09/13/1999. LexicalTag NON. ThesaurusID NLM (1999). ... Cloprostenol Preferred Term Term UI T008736. Date01/01/1999. LexicalTag NON. ThesaurusID ...
Cloprostenol,N0000011472, Urate Oxidase,N0000011471, 3-Hydroxybutyric Acid,N0000011470, Hydroxybutyrates,N0000011469, ...
Hryciuk MM, Jewgenow K, Braun BC (2021): Cloprostenol, a synthetic analog of prostaglandin F2α induces functional regression in ...
... cloprostenol). This hormone treatment resulted in a higher conception rate in all treated animals and significantly impacted ... cloprostenol). This hormone treatment resulted in a higher conception rate in all treated animals and significantly impacted ...
In conjunction with the 6th dose of FOLLTROPIN®, administer an FDA-approved prostaglandin product (cloprostenol sodium or ...
Animals, Cloprostenol, Female, Hormone Antagonists, Luteal Phase, Mifepristone, Ovary, Oxytocin, Progesterone, Random ... 250 microg cloprostenol), venous blood samples were collected at frequent intervals to determine plasma oxytocin concentrations ...
Investors. You are an investor, an analyst or an individual shareholder and have a question about EUROAPI, please contact the Investor Relations department.. The role of the Investor Relations department is to maintain a transparent and comprehensive dialogue with the financial community about EUROAPIs strategy, outlook and financial data, its economic environment and any other useful information.. Sophie Palliez. Head of Investor ...
Cloprostenol * Pigs POM-V United Kingdom Progressis Emulsion for Injection for Pigs (Sows and Gilts) Ceva Animal Health Ltd ...
Cloprostenol Sodium Entry term(s). Cloprostenol Monosodium Salt Monosodium Salt, Cloprostenol Salt, Cloprostenol Monosodium ... Monosodium Salt, Cloprostenol. Oestrophan. Salt, Cloprostenol Monosodium. Sodium, Cloprostenol. Tree number(s):. D10.251. ... Cloprostenol Monosodium Salt. Cloprostenol Sodium. Estrumate. ICI 80,966. ICI-80,966. ICI80,966. ... Cloprostenol - Preferred Concept UI. M0004625. Scope note. A synthetic prostaglandin F2alpha analog. The compound has ...
Cloprostenol D10.251.355.255.550.700.500.175 D10.251.355.255.550.775.500.175 D23.469.50.175.725.775.500.175 Clostridium B3.353. ...
Cloprostenol Sodium Narrower Concept UI. M0351575. Registry Number. 886SAV9675. Terms. Cloprostenol Sodium Preferred Term Term ... Cloprostenol Monosodium Salt Cloprostenol Sodium Estrumate ICI-80,966 Oestrophan Pharm Action. Luteolytic Agents. Registry ... Cloprostenol Monosodium Salt Term UI T360764. Date09/13/1999. LexicalTag NON. ThesaurusID NLM (1999). ... Cloprostenol Preferred Term Term UI T008736. Date01/01/1999. LexicalTag NON. ThesaurusID ...
Cloprostenol (5) * Síndrome de Exfoliação (5) * COVID-19 (5) * Complicações Pós-Operatórias (4) ...
5,510,383 (Use of Cloprostenol, Fluprostenol and Their Salts and Esters to Treat Glaucoma and Ocular Hypertension, issued ... Use of Cloprostenol and Fluprostenol Analogues to Treat Glaucoma and Ocular Hypertension, issued March 30, 1999), 6,011,062 ( ...
ENGLISH ABSTRACT: 1. Preliminary observations proved that an intramuscular injection of 62,5pg Cloprostenol terminates the ...
Veterinary Drugs GMP Certificate Competitive Price Cloprostenol Sodium CAS 55028-72-3 US $ 185-220 / G FOB ...
Bimeda has grown into a leading global manufacturer and distributor of veterinary pharmaceuticals and animal health products. Bimeda is focused on providing a comprehensive, customer driven service, selling consistently high-quality products, at a market-conscious price level.
Chloranil;Benzyl alcohol;2-Phenylphenol

Dye intermediate:1,4-Diaminoanthraquinone; 1,4-Dioxyanthraquinone;Solvent Violet 47

Iron chlorides Series:FeCl2.4(H2O);FeCl2.2H2O;Ferric Chloride solution
PGF2a Cloprostenol Carus Laboratory.. Chat To Order PGF2a Zolcol Injection 2ml. Read more ...
MSD Animal Health is a global leader in the animal health market, in the manufacturing, marketing, research and development of animal health products.
Oxyject 20%® LA-- Infectious pneumonia caused by stress and shipping fever.- Infectious gastroenteritis- Metritis Syndrome
Dalmazin SYNCH 0,075 mg/ml инжекционен разтвор за говеда, свине и коне
... cloprostenol, E0301305,Prostenon,dinoprostone, E0301307,Venosmine,diosmin, E0301311,Dipel,bitoxibacillin, E0301313,Allerdryl, ... cloprostenol, E0301587,Novidium,ethidium, E0301594,Trecator,ethionamide, E0301597,Epodyl,ethoglucid, E0301602,Suxilep, ... cloprostenol, E0301030,Tranxilium,clorazepate dipotassium, E0301034,Clostilbegit,enclomiphene citrate, E0301035,Klostilbegit, ...
High quality Chryanthemum Parthenium Natural Cosmetic Ingredients CAS 20554 84 1 Anti Inflammatory from China, Chinas leading centella asiatica extract product, with strict quality control cosmetic plant extract factories, producing high quality cosmetic plant extract products.
Cloprostenol Sodium Injection Vet Medicine. Contact Now Cloprostenol Sodium for Injection. Contact Now ...
Cloprostenol Injection. Physical Form : Liquid. Medicine Type : Veterinary Injectables. Price : 191 INR. Minimum Order Quantity ...
  • 17. Luteolytic effects of cloprostenol sodium in lactating dairy cows treated with G6G/Ovsynch. (nih.gov)
  • In conjunction with the 6 th dose of FOLLTROPIN ® , administer an FDA-approved prostaglandin product (cloprostenol sodium or dinoprost tromethamine) for cattle, using the labeled dosage and administration instructions to cause luteolysis and induce estrus. (nih.gov)
  • GC16838 (±)-Cloprostenol sodium salt (±)-클로프로스테놀 나트륨염(ICI 80996 나트륨염)은 강력한 합성 프로스타글란딘 유사체이며 황체 용해제로 작용하며 PGF2α 수용체 작용제입니다. (glpbio.com)
  • GC45259 (+)-Cloprostenol (sodium salt) (+)-Cloprostenol (sodium salt) is a more water soluble, crystalline form of (+)-cloprostenol. (glpbio.com)
  • GONAbreed ® (gonadorelin acetate), in combination with estroPLAN ® (cloprostenol sodium), can be used safely and effectively in various timed breeding programs. (parnell.com)
  • The cow was diagnosed as mucometra due to follicular cyst and treated with ovsynch plus CIDR protocol using 20礸 of GnRH and cloprostenol sodium of 500 礸 and CIDR device containing progesterone of 1.9 gms. (who.int)
  • Roles of cyclic AMP and inositol phosphates in the luteolytic action of cloprostenol, a prostaglandin F2 alpha analogue, in marmoset monkeys (Callithrix jacchus). (nih.gov)
  • 3. Cloprostenol, a prostaglandin F(2alpha) analog, induces hypoxia in rat placenta: BOLD contrast MRI. (nih.gov)
  • Cows diagnosed with RBS were administrated hormone therapy based on the Double Ovsynch protocol with applications of gonadotropin-releasing hormone (GnRH) and a prostaglandin analogue (cloprostenol). (tubitak.gov.tr)
  • On day 8, after an i.v. injection with prostaglandin F(2alpha) (250 microg cloprostenol), venous blood samples were collected at frequent intervals to determine plasma oxytocin concentrations. (oregonstate.edu)
  • On day 7 these cows were given prostaglandin F2α (PGF2α) analogue cloprostenol (Estrumate®, Intervet Deutschland GmbH, 0.5mg per animal i.m.), and the CIDR® insert was removed. (fu-berlin.de)
  • A single intramuscular injection of 0.5 micrograms cloprostenol was not luteolytic on Day 6 or 7 of the ovarian cycle (N = 3), but was luteolytic in some animals (3/5) on Day 8 and 9 and luteolytic in all 23 animals treated between Days 10 and 17 of the ovarian cycle, and in 7 animals treated between Days 19 and 43 of pregnancy. (nih.gov)
  • The interval from cloprostenol injection to ovulation in animals treated between Days 8 and 17 was 10.7 +/- 0.3 days. (nih.gov)
  • Preliminary observations proved that an intramuscular injection of 62,5pg Cloprostenol terminates the oestrus cycle of ewes. (sun.ac.za)
  • En une injection intramusculaire hebdomadaire de testostérone. (nipponcha.jp)
  • GC30743 (+)-Cloprostenol (D-Cloprostenol) (+)-클로프로스테놀(D-Cloprostenol)은 프로스타글란딘 F2α (PGF2α) 유사체이며, 프로스타글란딘 수용체에서 선택적 작용 활성을 나타냅니다. (glpbio.com)
  • In the PG group (n=98) all heifers were given PGF2α analogue cloprostenol on day 7. (fu-berlin.de)